Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BLUSF NASDAQ:IGMS NASDAQ:MDGL NASDAQ:NBRV NASDAQ:TBPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUSFBELLUS Health$9.77$0.49▼$2.60$2.35B1.5539,610 shs3.45 million shsIGMSIGM Biosciences$1.27$1.28$0.92▼$22.50$76.57M0.6480,746 shsN/AMDGLMadrigal Pharmaceuticals$440.75+5.6%$374.33$200.63▼$457.16$9.27B-1.02326,654 shs475,049 shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shs177 shsTBPHTheravance Biopharma$14.47+3.0%$12.62$7.88▼$14.55$707.58M0.05510,950 shs442,496 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUSFBELLUS Health0.00%0.00%0.00%0.00%0.00%IGMSIGM Biosciences0.00%0.00%0.00%+8.55%-92.37%MDGLMadrigal Pharmaceuticals+5.59%+0.30%+16.12%+54.25%+89.03%NBRVNabriva Therapeutics0.00%0.00%0.00%0.00%+4,900.00%TBPHTheravance Biopharma+2.99%+5.62%+7.58%+36.12%+74.97%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUSFBELLUS Health$9.77$0.49▼$2.60$2.35B1.5539,610 shs3.45 million shsIGMSIGM Biosciences$1.27$1.28$0.92▼$22.50$76.57M0.6480,746 shsN/AMDGLMadrigal Pharmaceuticals$440.75+5.6%$374.33$200.63▼$457.16$9.27B-1.02326,654 shs475,049 shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shs177 shsTBPHTheravance Biopharma$14.47+3.0%$12.62$7.88▼$14.55$707.58M0.05510,950 shs442,496 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUSFBELLUS Health0.00%0.00%0.00%0.00%0.00%IGMSIGM Biosciences0.00%0.00%0.00%+8.55%-92.37%MDGLMadrigal Pharmaceuticals+5.59%+0.30%+16.12%+54.25%+89.03%NBRVNabriva Therapeutics0.00%0.00%0.00%0.00%+4,900.00%TBPHTheravance Biopharma+2.99%+5.62%+7.58%+36.12%+74.97%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUSFBELLUS Health 0.00N/AN/AN/AIGMSIGM Biosciences 1.89Reduce$4.89284.95% UpsideMDGLMadrigal Pharmaceuticals 2.90Moderate Buy$483.389.67% UpsideNBRVNabriva Therapeutics 0.00N/AN/AN/ATBPHTheravance Biopharma 3.20Buy$23.0058.95% UpsideCurrent Analyst Ratings BreakdownLatest TBPH, MDGL, NBRV, IGMS, and BLUSF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/15/2025TBPHTheravance BiopharmaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/12/2025MDGLMadrigal PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$428.00 ➝ $526.009/12/2025TBPHTheravance BiopharmaB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$28.009/11/2025TBPHTheravance BiopharmaB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/4/2025MDGLMadrigal PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$500.008/26/2025MDGLMadrigal PharmaceuticalsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/26/2025MDGLMadrigal PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$390.00 ➝ $554.008/20/2025MDGLMadrigal PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$483.00 ➝ $485.008/15/2025TBPHTheravance BiopharmaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/12/2025MDGLMadrigal PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$458.00 ➝ $523.008/6/2025MDGLMadrigal PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$420.00 ➝ $428.00(Data available from 9/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUSFBELLUS Health$30K0.00N/AN/A$0.25 per share0.00IGMSIGM Biosciences$145.05M0.53N/AN/A$1.67 per share0.76MDGLMadrigal Pharmaceuticals$180.13M54.32N/AN/A$34.59 per share12.74NBRVNabriva Therapeutics$35.59M0.00N/AN/A$0.10 per share0.00TBPHTheravance Biopharma$64.38M11.32N/AN/A$3.57 per share4.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUSFBELLUS Health-$7.01M-$0.10N/AN/AN/A-49,910.34%-48.37%-45.25%N/AIGMSIGM Biosciences-$195.79M-$0.90N/AN/AN/A-36.81%-93.35%-24.15%11/14/2025 (Estimated)MDGLMadrigal Pharmaceuticals-$465.89M-$12.85N/AN/AN/A-54.68%-38.38%-27.32%10/30/2025 (Estimated)NBRVNabriva Therapeutics-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/ATBPHTheravance Biopharma-$56.42M$0.2460.2941.34N/A16.88%6.93%3.52%11/11/2025 (Estimated)Latest TBPH, MDGL, NBRV, IGMS, and BLUSF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025MDGLMadrigal Pharmaceuticals-$3.48-$1.90+$1.58-$1.90$158.94 million$212.80 million7/31/2025Q2 2025IGMSIGM Biosciences-$0.30$1.58+$1.88$1.58$3.20 million$143.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLUSFBELLUS HealthN/AN/AN/AN/AN/AIGMSIGM BiosciencesN/AN/AN/AN/AN/AMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/ANBRVNabriva TherapeuticsN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUSFBELLUS HealthN/A13.8713.87IGMSIGM BiosciencesN/A17.6617.66MDGLMadrigal Pharmaceuticals0.175.114.78NBRVNabriva Therapeutics0.120.850.52TBPHTheravance BiopharmaN/A6.706.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUSFBELLUS HealthN/AIGMSIGM Biosciences42.79%MDGLMadrigal Pharmaceuticals98.50%NBRVNabriva Therapeutics0.27%TBPHTheravance Biopharma99.10%Insider OwnershipCompanyInsider OwnershipBLUSFBELLUS Health24.17%IGMSIGM Biosciences57.00%MDGLMadrigal Pharmaceuticals21.50%NBRVNabriva Therapeutics1.63%TBPHTheravance Biopharma6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLUSFBELLUS Health10159.12 millionN/ANot OptionableIGMSIGM Biosciences19060.29 million25.93 millionOptionableMDGLMadrigal Pharmaceuticals9022.20 million17.43 millionOptionableNBRVNabriva Therapeutics7032.02 million31.49 millionNot OptionableTBPHTheravance Biopharma11050.36 million46.89 millionOptionableTBPH, MDGL, NBRV, IGMS, and BLUSF HeadlinesRecent News About These CompaniesTheravance Biopharma, Inc. (NASDAQ:TBPH) Short Interest Up 25.3% in AugustSeptember 19 at 3:29 AM | americanbankingnews.comTheravance Biopharma (NASDAQ:TBPH) Downgraded to "Hold" Rating by Zacks ResearchSeptember 18 at 6:43 AM | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Stock Rating Lowered by Zacks ResearchSeptember 18 at 3:25 AM | americanbankingnews.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Sees Significant Increase in Short InterestSeptember 18 at 2:35 AM | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Reaches New 1-Year High - Here's WhySeptember 17 at 10:44 AM | marketbeat.comAcadian Asset Management LLC Buys 174,451 Shares of Theravance Biopharma, Inc. $TBPHSeptember 17 at 3:17 AM | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by B. RileySeptember 15, 2025 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Receives $23.00 Consensus Target Price from BrokeragesSeptember 15, 2025 | americanbankingnews.comTheravance Biopharma (NASDAQ:TBPH) Shares Up 4.6% - Should You Buy?September 14, 2025 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of "Buy" from BrokeragesSeptember 14, 2025 | marketbeat.comB. Riley Initiates Coverage on Theravance Biopharma (NASDAQ:TBPH)September 14, 2025 | marketbeat.comTheravance Biopharma, Inc. $TBPH Shares Sold by Jacobs Levy Equity Management Inc.September 14, 2025 | marketbeat.comB. Riley Begins Coverage on Theravance Biopharma (NASDAQ:TBPH)September 13, 2025 | americanbankingnews.com46,972 Shares in Theravance Biopharma, Inc. $TBPH Bought by Cubist Systematic Strategies LLCSeptember 13, 2025 | marketbeat.comB. Riley Securities Initiates Coverage of Theravance Biopharma (TBPH) with Buy RecommendationSeptember 12, 2025 | msn.comTheravance Biopharma initiated with a Buy at B. RileySeptember 12, 2025 | msn.comTheravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue?September 11, 2025 | zacks.comInvesco Ltd. Sells 23,515 Shares of Theravance Biopharma, Inc. $TBPHSeptember 10, 2025 | marketbeat.comQ3 Earnings Estimate for TBPH Issued By Zacks ResearchSeptember 7, 2025 | marketbeat.comTheravance Biopharma, Inc. $TBPH Shares Bought by PDT Partners LLCSeptember 6, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Hits New 12-Month High - Should You Buy?September 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTBPH, MDGL, NBRV, IGMS, and BLUSF Company DescriptionsBELLUS Health OTCMKTS:BLUSFBELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.IGM Biosciences NASDAQ:IGMSIGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.Madrigal Pharmaceuticals NASDAQ:MDGL$440.75 +23.32 (+5.59%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$440.90 +0.15 (+0.03%) As of 08:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.Nabriva Therapeutics NASDAQ:NBRVNabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.Theravance Biopharma NASDAQ:TBPH$14.47 +0.42 (+2.99%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$14.48 +0.00 (+0.03%) As of 08:53 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Joby's Stock Is Quiet, But Its Commercial Engine Is In Overdrive Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Bloom Energy Booms on AI Power Demand and Analyst Upgrades Can Apple’s iPhone 17 and AI Push Its Stock to New Highs? Why Seagate Is Wall Street's New Favorite AI Infrastructure Play New Catalysts Build Positive Pressure on Intel Stock Oracle to Hit $1 Trillion Valuation in 2025: Here’s Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
